Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  PCAS    PCA   FR0000053514

PCAS (PCA)

Delayed Quote. Delayed  - 02/23 05:35:13 pm
13.99 EUR   +2.04%
02/21 PCAS : 2016 Annual Results
01/31 PCAS : Net Sales as at December 31, 2016
2016 PCAS : Acquisition of a leading R&D Center
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

PCAS : Extension of the manufacturing between VLG Chem and Sanofi

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/29/2011 | 11:11am CET
Extension of the manufacturing contract between VLG Chem and  Sanofi until 2015 The PCAS Group and the Sanofi Group have signed an agreement on the extension of the manufacturing contract related to VLG Chem, a 100% PCAS subsidiary, until 2015. About PCAS PCAS is a fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability.
Longjumeau, december 27th, 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PCAS
02/21 PCAS : 2016 Annual Results
01/31 PCAS : Net Sales as at December 31, 2016
2016 PCAS : Acquisition of a leading R&D Center
2016 PCAS : Acquisition of a leading r&d center
2016 PCAS : at China INTER LUBRIC 2016
2016 PCAS : net sales as of 30 September, 2016
2016 PCAS : ex-dividend day for interim dividend
2016 PCAS : 1st half 2016 earnings report continued organic growth
2016PCAS : half-yearly earnings release
2016 PCAS : Net sales for the 1st half of 2016
More news
Sector news : Pharmaceuticals - NEC
11:51aDJGlaxoSmithKline Reports Positive Study Results for Asthma Drug
10:23aDJPURETECH HEALTH : Appoints Atul Pande as Chief Medical Officer
08:49aDJBAYER : Financing Plan Will Raise Equity First Then Bonds -- WSJ
08:49aDJBAYER : CEO Still Upbeat on Deal -- WSJ
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
More sector news : Pharmaceuticals - NEC
Advertisement
Financials (€)
Sales 2017 206 M
EBIT 2017 19,4 M
Net income 2017 11,1 M
Debt 2017 43,1 M
Yield 2017 1,26%
P/E ratio 2017 16,86
P/E ratio 2018 14,04
EV / Sales 2017 1,22x
EV / Sales 2018 1,13x
Capitalization 208 M
More Financials
Chart PCAS
Duration : Period :
PCAS Technical Analysis Chart | PCA | FR0000053514 | 4-Traders
Full-screen chart
Technical analysis trends PCAS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 13,6 €
Spread / Average Target -0,80%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Vincent Touraille CEO & Financial Communications Contact
Christian Moretti Chairman
Pierre Schreiner Deputy Chief Executive Officer-Operations
Eric Moissenot Deputy CEO-Finance & Administration
Gérard Guillamot Director-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PCAS-2.21%219
JOHNSON & JOHNSON3.86%325 158
ROCHE HOLDING LTD.5.98%210 992
PFIZER INC.3.51%203 836
NOVARTIS AG3.51%202 566
MERCK & CO., INC.11.23%180 014
More Results